Robin and Orégane join us to develop a microfluidic system for mechanical sollicitation of cancer spheroids

As part of their engineering studies at ISEN Lille for a master’s degree specialized in Bionanotechnologies, Robin and Orégane arrived in HCS Pharma in May 2021 for a 4-month internship. Their work in HCS Pharma follows a student project during which they designed and computationally simulated a microfluidic device capable Read more…

Our next webinar with Molecular Devices : A physiologically-relevant 3D ECM for in vitro oncology research and intelligent high-content imaging of 3D models

We are very happy to invite you to our next webinar about 3D cellular cancer models and our BIOMIMESYS® Oncology matrix which allows cancer cells to be cultured in a tumor-like environment, with the possibility to tune the composition and stiffness of the matrix. We will also share our best Read more…

The key role of appropriate microenvironnement in your 3D cellular assays

Context It is well established that the extracellular matrix (ECM) plays a central role in cell homeostasis and cell adhesion by providing support, promoting cell-to-cell communication and differentiation (or dedifferentiation and tumoral progression when the ECM is modified). The composition but also the stiffness and elasticity of the ECM have important Read more…

Artificial intelligence to improve 3D cell culture : a milestone for HCS pharma

As you may now, in HCS Pharma we strongly believe that the critical point of the human health evolution in next years is the in vitro 3D cell culture, especially for complex diseases like cancer [1]. It’s why we work hard on our exclusive BIOMIMESYS® technology. As experts in HCS and cell imaging, we must master all the process : 3D biological models, 3D cell culture, volumetric pictures acquisition, 3D reconstruction and segmentation of cells and ECM compounds, 3D parameters extraction and, of course, biological interpretations. As explained in our VisuAI R&D project, the 3D reconstruction and segmentation step is not simple.

New 384-well plates format for BIOMIMESYS® Liver & Oncology entitling Cell-Based Assays High-Throughput Screening

HCS-Pharma is pleased to launch BIOMIMESYS® Liver and Oncology in ready-to-use 384-well plate format for screening applications. Adopt BIOMIMESYS® 3D cell culture systems and obtain more predictive in vitro models. You can find our presentations in PDF format for BIOMIMESYS® Liver for BIOMIMESYS® Oncology For more information, contact us at hello@biomimesys.com

3D co-culture of dopaminergic neurons and astrocytes in BIOMIMESYS® Brain to study Parkinson’s disease

Parkinson’s disease affects more than 6 million people worldwide. This neurodegenerative disease is characterized by the death of dopaminergic neurons in the substantia nigra pars compacta, with intracellular accumulation of alpha-synuclein aggregates known as Lewi bodies. This neuronal loss leads to a decrease in the neurotransmitter dopamine that cause mainly Read more…

ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma

Abstract The ATP Binding Cassette transporter B1 (ABCB1) induces chemoresistance in osteosarcoma, because it effluxes doxorubicin, reducing the intracellular accumulation, toxicity, and immunogenic cell death induced by the drug. The ATP Binding Cassette transporter A1 (ABCA1) effluxes isopentenyl pyrophosphate (IPP), a strong activator of anti-tumor Vγ9Vδ2 T-cells. Recruiting this population Read more…